Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Cash (2016 - 2025)

OptimizeRx's Change in Cash history spans 16 years, with the latest figure at $2.9 million for Q3 2025.

  • For Q3 2025, Change in Cash rose 151.41% year-over-year to $2.9 million; the TTM value through Sep 2025 reached $3.4 million, down 45.31%, while the annual FY2024 figure was -$472000.0, 89.17% up from the prior year.
  • Change in Cash for Q3 2025 was $2.9 million at OptimizeRx, up from $12000.0 in the prior quarter.
  • Across five years, Change in Cash topped out at $71.8 million in Q1 2021 and bottomed at -$46.1 million in Q3 2022.
  • The 5-year median for Change in Cash is $115000.0 (2023), against an average of $473784.7.
  • The largest annual shift saw Change in Cash surged 2070.07% in 2021 before it tumbled 6068.58% in 2022.
  • A 5-year view of Change in Cash shows it stood at -$374808.0 in 2021, then crashed by 6068.58% to -$23.1 million in 2022, then surged by 117.0% to $3.9 million in 2023, then plummeted by 169.87% to -$2.7 million in 2024, then skyrocketed by 206.85% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Change in Cash are $2.9 million (Q3 2025), $12000.0 (Q2 2025), and $3.2 million (Q1 2025).